Boehringer Ingelheim collaborates with Cue Biopharma to develop next-generation treatment for autoimmune and inflammatory diseases
Tuesday, April 15, 2025
Boehringer Ingelheim has entered into a strategic research collaboration and licensing agreement with Cue Biopharma to develop and commercialise a potential new treatment, CUE-501, for autoimmune conditions. Cue Biopharma is a clinical-stage company focused on creating a new class of therapeutic biologics aimed at engaging and modulating disease-specific T cells for the treatment of autoimmune and inflammatory diseases.
CUE-501, a preclinical candidate, targets a specific protein on the surface of B cells while also engaging virus-specific memory T cells. This dual mechanism allows for the selective depletion of B cells, helping to reduce autoimmune and inflammatory activity. The approach aims to provide better results and safety compared to existing B cell therapies.
The collaboration will use Cue Biopharma’s technology to support further research and progress the development of the candidate molecule. The agreement also includes the option to expand efforts into other bispecific therapies that target B cells across a range of autoimmune diseases.
As part of the agreement, Cue Biopharma will receive an initial payment of $12 million and additional research support. The company may also receive up to $345 million in milestone payments linked to research, development, and commercial achievements, along with royalties on future net sales.
Source: globenewswire.com
